{"protocolSection":{"identificationModule":{"nctId":"NCT01865487","orgStudyIdInfo":{"id":"C-035-456"},"organization":{"fullName":"Aeras","class":"OTHER"},"briefTitle":"A Phase I/IIa AERAS-456 in HIV-Negative Adults With & Without Latent Tuberculosis Infection (C-035-456)","officialTitle":"A Phase I/IIa Double-Blind, Randomized, Placebo-controlled Dose-Finding Study to Evaluate the Safety and Immunogenicity of AERAS-456 in HIV-Negative Adults With and Without Latent Tuberculosis Infection"},"statusModule":{"statusVerifiedDate":"2019-12","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2013-08"},"primaryCompletionDateStruct":{"date":"2015-08","type":"ACTUAL"},"completionDateStruct":{"date":"2015-11","type":"ACTUAL"},"studyFirstSubmitDate":"2013-05-21","studyFirstSubmitQcDate":"2013-05-28","studyFirstPostDateStruct":{"date":"2013-05-31","type":"ESTIMATED"},"resultsFirstSubmitDate":"2019-04-23","resultsFirstSubmitQcDate":"2019-12-03","resultsFirstPostDateStruct":{"date":"2019-12-19","type":"ACTUAL"},"lastUpdateSubmitDate":"2019-12-03","lastUpdatePostDateStruct":{"date":"2019-12-19","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Aeras","class":"OTHER"},"collaborators":[{"name":"Statens Serum Institut","class":"OTHER"}]},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"This is a Phase I/IIa, double-blind, randomized, placebo-controlled, dose- and regimen-finding study in healthy adults with and without LTBI, who are BCG-vaccinated, HIV negative, and have no history or evidence of TB disease. The investigational product is AERAS-456 at 3 dose levels: 5, 15, and 50ug of H56 antigen with 500 nmol IC31. The vaccine is administered by IM injection.","detailedDescription":"This is a Phase I/IIa, double-blind, randomized, placebo-controlled, dose- and regimen-finding study in healthy adults with and without latent Tuberculosis (TB) Infection, who are Bacille Calmette Guerin (BCG)-vaccinated, HIV negative, and have no history or evidence of TB disease. The investigational product is AERAS-456 at 3 dose levels: 5, 15, and 50ug of H56 antigen with 500 nmol IC31. The vaccine is administered by intramuscular (IM) injection. The study will be conducted at two sites in South Africa.\n\nA total of 98 subjects will be enrolled in 2 phases into 4 groups based on Latent TB Infection (LTBI) status. The initial phase will be a dose ranging study of a 2-dose regimen at 3 dosage levels in LTBI(-) subjects, to select a dosage for the second phase. In the second phase, the study will be expanded to evaluate both 2-dose and 3-dose regimens and to include LTBI(+) subjects. In the first phase, 50 LTBI(-) subjects will be enrolled in Group 1 and randomized at a ratio of 3:3:3:1 to receive 2 doses of 5/500, 15/500, or 50/500 of AERAS-456, or placebo given at Study Days 0 and 56 (Table 0 1).\n\nOne dose level of AERAS-456 will be selected by the sponsor and SSI for the second phase of the study, based on analysis of unblinded safety and immunogenicity data through 28 days after the second dose in the first phase, in conjunction with safety and immunogenicity data from study C-032-456. The criteria for dose-selection will be specified in a statistical analysis plan to be finalized prior to the unblinded review. The selected dose, in conjunction with the unblinded safety and immunogenicity data, will be submitted to the SMC for review. In the second phase, 48 subjects will be enrolled concurrently into Group 2 (LTBI\\[-\\]) and into Groups 3 and 4 (LTBI\\[+\\], Table 0 2). In each of Groups 2 and 4, 16 subjects will be randomized at a ratio of 3:1 to receive 3 doses of AERAS-456 or placebo given at Study Days 0, 56, and 112. In Group 3, 16 subjects will be randomized at a ratio of 3:1 to receive 2 doses of AERAS-456 or placebo given at Study Days 0 and 56.\n\nAll subjects will stay on the study for 292 days after receiving the first vaccination. The subjects in Groups 1 and 3 will be followed up for 236 days after the second vaccination and subjects in Groups 2 and 4 will be followed up for 180 days after the third vaccination. The sample size for each study cohort was selected because it was judged to be adequate for preliminary safety and immunogenicity evaluations for a Phase I/IIa study rather than for statistical reasons. Given 12 and 15 subjects in individual AERAS-456 dosing groups, the study will have an 80% probability of detecting at least 1 specified event which occurs at a rate of 12.5% and 10.0%, respectively. If no such events are observed among 12 and 15 subjects receiving active study vaccine, an approximation to the upper one-sided 95% confidence bound on the rate of occurrence for that event would be 22% and 18%, respectively."},"conditionsModule":{"conditions":["Latent Tuberculosis Bacteriology and Histology Unknown","Latent Tuberculosis"],"keywords":["BCG Vaccinated","HIV Negative"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1","PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"SEQUENTIAL","interventionModelDescription":"A 2 phase study based on LTBI status. Phase 1 is a dose ranging study of a 2 dose regimen at 3 dosage levels and placebo in LTBI negative participants. The second phase evaluated 2 and 3 dose regimens and included + and - LTBI participants.","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":98,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"2-Dose Placebo","type":"PLACEBO_COMPARATOR","description":"Placebo QFT Neg and Pos, 2 Doses, days 0,56","interventionNames":["Biological: Placebo"]},{"label":"2-Dose 5/500 H56ug/IC31nmol","type":"EXPERIMENTAL","description":"5/500 H56ug/IC31nmol QFT Neg and Pos, 2 Doses, days 0,56","interventionNames":["Biological: H56ug/IC31nmol"]},{"label":"2-Dose 15/500 H56ug/IC31nmol","type":"EXPERIMENTAL","description":"15/500 H56ug/IC31nmol QFT Negative 2 Doses, days 0,56","interventionNames":["Biological: H56ug/IC31nmol"]},{"label":"2-Dose 50/500 H56ug/IC31nmol","type":"EXPERIMENTAL","description":"50/500 H56ug/IC31nmol QFT Negative 2 Doses, days 0,56","interventionNames":["Biological: H56ug/IC31nmol"]},{"label":"3-Dose, Placebo","type":"PLACEBO_COMPARATOR","description":"Placebo QFT Neg and Pos, 3 doses, days 0, 56, 112","interventionNames":["Biological: Placebo"]},{"label":"3-Dose, 5/500 H56ug/IC31nmol","type":"EXPERIMENTAL","description":"5/500 H56ug/IC31nmol QFT Neg and Pos, 3 Doses, days 0, 56, 112","interventionNames":["Biological: H56ug/IC31nmol"]}],"interventions":[{"type":"BIOLOGICAL","name":"H56ug/IC31nmol","description":"H56:IC31 (designated as AERAS-456 for Aeras-sponsored clinical development) contains a fusion protein (referred to as H56 antigen, or H56) of 3 mycobacterial antigens (the early secreted antigens Ag85B and ESAT-6, and the latency antigen Rv2660c) formulated in the Th1-stimulating IC31 adjuvant.","armGroupLabels":["2-Dose 15/500 H56ug/IC31nmol","2-Dose 5/500 H56ug/IC31nmol","2-Dose 50/500 H56ug/IC31nmol","3-Dose, 5/500 H56ug/IC31nmol"],"otherNames":["AERAS-456"]},{"type":"BIOLOGICAL","name":"Placebo","description":"Sterile buffer consisting of 10mM Tris and 169mM NaCl at pH 7.4","armGroupLabels":["2-Dose Placebo","3-Dose, Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number and Percentage of Unsolicited and Solicited Adverse Events Recorded Post Day 0 Vaccination.","description":"Evaluation of unsolicited and solicited AEs was performed through 28 days after each study vaccination. Serious AEs were collected throughout the entire study period (i.e., 292 days). Evaluation of the safety profile of AERAS-456 was performed using data from all subjects who received at least one dose.","timeFrame":"Up to 10 months"}],"secondaryOutcomes":[{"measure":"Evaluate Immunogenicity of Multiple Dosage Levels and Dosing Regimens of H56:IC31 - CD4+ ICS (LTBI-negative)","description":"LTBI: Latent TB Infection QFT: QuantiFERON-TB Gold Plus (QFT-Plus) is an in vitro diagnostic aid for detection of Mycobacterium tuberculosis infection Percent Antigen-specific T Cell DMSO-subtracted Cytokine Response Change from Baseline 13-color ICS assay using PBMCs T Cell: CD4+ Stimulation Antigen: Total Cytokine: Any","timeFrame":"Day 292"},{"measure":"Evaluate Immunogenicity of Multiple Dosage Levels and Dosing Regimens of H56:IC31 - CD4+ ICS (LTBI-positive)","description":"Percent Antigen-specific T Cell DMSO-subtracted Cytokine Response Change from Baseline.\n\n13-color ICS assay using PBMCs. T Cell: CD4+ Stimulation Antigen: Total Cytokine: Any","timeFrame":"Day 292"},{"measure":"Evaluate Immunogenicity of Multiple Dosage Levels and Dosing Regimens of H56:IC31 - IFN-gamma ELISpot","description":"DMSO-subtracted Antigen-specific IFN-gamma ELISpot Response (SFU - Background/10\\^6 PBMC) Change from Baseline LTBI Status at Baseline: Total Stimulation Antigen: Total","timeFrame":"Day 292"},{"measure":"Evaluate Kinetics of QuantiFERON®-TB Gold Test (QFT) Responses in LTBI-negative Participants","description":"QFT results were summarized using subject count (percentage) for qualitative results.\n\nNumber of participants QFT-positive at any time point.","timeFrame":"Up to Study Day 292"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nSubjects must meet all of the following criteria prior to Study Day 0 vaccination:\n\n1. Has completed the written informed consent process prior to the start of screening evaluations.\n2. Is male or female.\n3. Is age 18 through 50 years at the time of randomization.\n4. Received BCG vaccination at least 5 years prior to randomization.\n5. Females: Ability to avoid pregnancy during the trial: Women physically capable of pregnancy (not sterilized and still menstruating or within 1 year of the last menses if menopausal) in sexual relationships with men must avoid pregnancy with an acceptable method of avoiding pregnancy from 28 days prior to administration of the study vaccine through the end of the study.\n6. Has general good health, confirmed by medical history and physical examination at screening.\n7. Is able and willing to complete the full follow-up period of 292 days as required by the protocol.\n8. Agrees to avoid elective surgery for the full duration of the study.\n9. \\[Groups 1 and 2\\] Does not have LTBI, determined by a negative QFT at screening or\\[Groups 3 and 4\\] Has LTBI, determined by a positive QFT at screening.\n\nExclusion Criteria:\n\nSubjects must meet none of the following criteria prior to Study Day 0 vaccination:\n\n1. Acute illness at the time of randomization.\n2. Oral temperature 37.5 degrees C at the time of randomization.\n3. Abnormal laboratory values from blood collected within 21 days prior to Study Day 0 vaccination.\n4. Abnormal urinalysis that, in the opinion of the investigator, indicates systemic or local disease.\n5. History or evidence of tuberculosis disease, including but not limited to pulmonary tuberculosis, pleural tuberculosis, lymph node tuberculosis or tuberculosis meningitis.\n6. Received a TST within 21 days prior to a scheduled study vaccination.\n7. Received investigational Mtb vaccine at any time prior to Study Day 0.\n8. History or evidence of autoimmune disease.\n9. History or laboratory evidence of HIV-1 infection at screening.\n10. Positive test for hepatitis B surface antigen or hepatitis C antibody at screening.\n11. Used immunosuppressive medication (other than inhaled or topical immunosuppressants) within 21 days prior to Study Day 0.\n12. Received immunoglobulin or blood products within 21 days prior to Study Day 0.\n13. Received any investigational product within 21 days prior to Study Day 0, or plans to participate in any other study involving administration of investigational product during the study period.\n14. Inability to discontinue current chronic prescription medications, except contraceptives, inhaled or topical immunosuppressants, or nutritional supplements, during the study period.\n15. Documented history of allergic reaction or hypersensitivity to any component of the study vaccine.\n16. All female subjects: currently pregnant or lactating/nursing; or positive serum pregnancy test during screening; or positive urine pregnancy test on the day of any study vaccination.\n17. History or evidence of any systemic disease or any acute or chronic illness that, in the opinion of the investigator, may compromise the safety of the subject in the study or interfere with the evaluation of the safety or immunogenicity of the vaccine.\n18. History of dermatologic disease or skin features that, in the opinion of the investigator, may interfere with the assessment of injection site reactions.\n19. History or evidence of any medical, psychiatric, occupational, or substance abuse problems that, in the opinion of the investigator, will make it unlikely that the subject will comply with the protocol.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"50 Years","stdAges":["ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Dereck Tait, MD","affiliation":"Aeras","role":"STUDY_DIRECTOR"},{"name":"Angelique Luabeya, MD","affiliation":"University of Cape Town South African Tuberculosis Vaccine Initiative","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"eKhayavac TB Vaccine Trial","city":"Khayelitsha","state":"Cape Town","zip":"7784","country":"South Africa","geoPoint":{"lat":-34.03932,"lon":18.67916}},{"facility":"SATVI Project Office, Brewelskloof Hospital","city":"Worcester","zip":"6850","country":"South Africa","geoPoint":{"lat":-33.64651,"lon":19.44852}}]},"referencesModule":{"references":[{"pmid":"30092143","type":"RESULT","citation":"Suliman S, Luabeya AKK, Geldenhuys H, Tameris M, Hoff ST, Shi Z, Tait D, Kromann I, Ruhwald M, Rutkowski KT, Shepherd B, Hokey D, Ginsberg AM, Hanekom WA, Andersen P, Scriba TJ, Hatherill M; H56-035 Trial Group. Dose Optimization of H56:IC31 Vaccine for Tuberculosis-Endemic Populations. A Double-Blind, Placebo-controlled, Dose-Selection Trial. Am J Respir Crit Care Med. 2019 Jan 15;199(2):220-231. doi: 10.1164/rccm.201802-0366OC."}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Group 1: 2-dose 5/500","description":"5/500 H56ug/IC31nmol, QFT Negative, 2 doses, days 0 and 56"},{"id":"FG001","title":"Group 1: 2-dose 15/500","description":"15/500 H56ug/IC31nmol, QFT Negative, 2 doses, days 0 and 56"},{"id":"FG002","title":"Group 1: 2-dose 50/500","description":"50/500 H56ug/IC31nmol, QFT Negative, 2 doses, days 0 and 56"},{"id":"FG003","title":"Group 1: 2-dose Placebo","description":"Placebo, QFT Negative, 2 doses, days 0 and 56"},{"id":"FG004","title":"Group 2: 3-dose 5/500","description":"5/500 H56ug/IC31nmol, QFT Negative, 3 doses, days 0, 56, 112"},{"id":"FG005","title":"Group 2: 3-dose Placebo","description":"Placebo, QFT Negative, 3 doses, days 0, 56, 112"},{"id":"FG006","title":"Group 3: 2-dose 5/500","description":"5/500 H56ug/IC31nmol, QFT Positive, 2 doses, Days 0 and 56"},{"id":"FG007","title":"Group 3: 2-dose Placebo","description":"Placebo, QFT Positive, 2 doses, Days 0 and 56"},{"id":"FG008","title":"Group 4: 3-dose 5/500","description":"5/500 H56ug/IC31nmol, QFT Positive, 3 doses, days 0, 56, 112"},{"id":"FG009","title":"Group 4: 3-dose Placebo","description":"Placebo, QFT positive, 3 doses, Days 0, 56, 112"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"15"},{"groupId":"FG001","numSubjects":"15"},{"groupId":"FG002","numSubjects":"15"},{"groupId":"FG003","numSubjects":"5"},{"groupId":"FG004","numSubjects":"12"},{"groupId":"FG005","numSubjects":"4"},{"groupId":"FG006","numSubjects":"12"},{"groupId":"FG007","numSubjects":"4"},{"groupId":"FG008","numSubjects":"12"},{"groupId":"FG009","numSubjects":"4"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"15"},{"groupId":"FG001","numSubjects":"15"},{"groupId":"FG002","numSubjects":"15"},{"groupId":"FG003","numSubjects":"4"},{"groupId":"FG004","numSubjects":"11"},{"groupId":"FG005","numSubjects":"4"},{"groupId":"FG006","numSubjects":"11"},{"groupId":"FG007","numSubjects":"4"},{"groupId":"FG008","numSubjects":"12"},{"groupId":"FG009","numSubjects":"4"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"1"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"}]}],"dropWithdraws":[{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"1"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"1"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"2-Dose Placebo","description":"Placebo, QFT Neg and Pos, 2 doses day 0 and 56"},{"id":"BG001","title":"2-Dose 5/500 H56/IC31nmol","description":"5/500 H56ug/IC31nmol, QFT Neg and Pos, 2 Doses, days 0 and 56"},{"id":"BG002","title":"2-Dose 15/500 H56/IC31nmol","description":"15/500 H56ug/IC31nmol, QFT Negative, 2 Doses, days 0 and 56"},{"id":"BG003","title":"2-Dose 50/500 H56/IC31nmol","description":"50/500 H56ug/IC31nmol, QFT Negative, 2 Doses, days 0 and 56"},{"id":"BG004","title":"3-Dose Placebo","description":"Placebo QFT Neg and Pos, 3 Doses, days 0, 56, 112"},{"id":"BG005","title":"3-Dose 5/500 H56/IC31nmol","description":"5/500 H56ug/IC31nmol, QFT Neg and Pos, 3 Doses, days 0, 56, 112"},{"id":"BG006","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"9"},{"groupId":"BG001","value":"27"},{"groupId":"BG002","value":"15"},{"groupId":"BG003","value":"15"},{"groupId":"BG004","value":"8"},{"groupId":"BG005","value":"24"},{"groupId":"BG006","value":"98"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"27.9","spread":"9.51"},{"groupId":"BG001","value":"27.2","spread":"8.71"},{"groupId":"BG002","value":"24.3","spread":"4.08"},{"groupId":"BG003","value":"25.3","spread":"8.76"},{"groupId":"BG004","value":"24.9","spread":"8.25"},{"groupId":"BG005","value":"28.4","spread":"8.34"},{"groupId":"BG006","value":"26.6","spread":"8.06"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"19"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"11"},{"groupId":"BG004","value":"6"},{"groupId":"BG005","value":"17"},{"groupId":"BG006","value":"66"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"8"},{"groupId":"BG002","value":"9"},{"groupId":"BG003","value":"4"},{"groupId":"BG004","value":"2"},{"groupId":"BG005","value":"7"},{"groupId":"BG006","value":"32"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"American Indian or Alaska Native","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"}]}]},{"title":"Asian","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"}]}]},{"title":"Black or African American","categories":[{"measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"9"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"7"},{"groupId":"BG004","value":"3"},{"groupId":"BG005","value":"8"},{"groupId":"BG006","value":"38"}]}]},{"title":"Native Hawaiian or Other Pacific Islander","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"}]}]},{"title":"White","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"}]}]},{"title":"Coloured","categories":[{"measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"18"},{"groupId":"BG002","value":"9"},{"groupId":"BG003","value":"8"},{"groupId":"BG004","value":"5"},{"groupId":"BG005","value":"16"},{"groupId":"BG006","value":"60"}]}]},{"title":"Other","categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"}]}]}]},{"title":"Baseline BMI","description":"Baseline Body Mass Index in kg/m\\^2","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"kg/m^2","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"26.83","spread":"8.385"},{"groupId":"BG001","value":"27.11","spread":"6.655"},{"groupId":"BG002","value":"25.74","spread":"8.122"},{"groupId":"BG003","value":"31.14","spread":"10.922"},{"groupId":"BG004","value":"27.75","spread":"12.612"},{"groupId":"BG005","value":"25.56","spread":"5.726"},{"groupId":"BG006","value":"27.17","spread":"8.191"}]}]}]},{"title":"LTBI Status at Baseline","description":"LTBI = Latent tuberculosis infection","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"LTBI Negative","measurements":[{"groupId":"BG000","value":"5"},{"groupId":"BG001","value":"15"},{"groupId":"BG002","value":"15"},{"groupId":"BG003","value":"15"},{"groupId":"BG004","value":"4"},{"groupId":"BG005","value":"12"},{"groupId":"BG006","value":"66"}]},{"title":"LTBI Positivie","measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"4"},{"groupId":"BG005","value":"12"},{"groupId":"BG006","value":"32"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Number and Percentage of Unsolicited and Solicited Adverse Events Recorded Post Day 0 Vaccination.","description":"Evaluation of unsolicited and solicited AEs was performed through 28 days after each study vaccination. Serious AEs were collected throughout the entire study period (i.e., 292 days). Evaluation of the safety profile of AERAS-456 was performed using data from all subjects who received at least one dose.","populationDescription":"Safety analysis set","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Participants","timeFrame":"Up to 10 months","groups":[{"id":"OG000","title":"Placebo QFT Neg","description":"2-doses and 3-doses (Groups 1 and 2)"},{"id":"OG001","title":"Placebo QFT Pos","description":"2-doses and 3-doses (Groups 3 and 4)"},{"id":"OG002","title":"2-Doses 5/500 QFT Neg","description":"QFT Negative (Group 1)"},{"id":"OG003","title":"2-Doses 15/500","description":"QFT Negative (Group 1)"},{"id":"OG004","title":"2-Doses 50/500","description":"QFT Negative (Group 1)"},{"id":"OG005","title":"3-Doses 5/500 QFT Neg","description":"QFT Negative (Group 2)"},{"id":"OG006","title":"2-Doses 5/500 QFT Pos","description":"QFT Positive (Group 3)"},{"id":"OG007","title":"3-Doses 5/500 QFT Pos","description":"QFT Positive (Group 4)"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"15"},{"groupId":"OG003","value":"15"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"12"},{"groupId":"OG006","value":"12"},{"groupId":"OG007","value":"12"}]}],"classes":[{"title":"Participants with AEs","categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"15"},{"groupId":"OG003","value":"15"},{"groupId":"OG004","value":"15"},{"groupId":"OG005","value":"10"},{"groupId":"OG006","value":"10"},{"groupId":"OG007","value":"10"}]}]},{"title":"Participants with related AEs","categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"11"},{"groupId":"OG004","value":"12"},{"groupId":"OG005","value":"6"},{"groupId":"OG006","value":"8"},{"groupId":"OG007","value":"8"}]}]},{"title":"Participants with SAEs","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"}]}]}]},{"type":"SECONDARY","title":"Evaluate Immunogenicity of Multiple Dosage Levels and Dosing Regimens of H56:IC31 - CD4+ ICS (LTBI-negative)","description":"LTBI: Latent TB Infection QFT: QuantiFERON-TB Gold Plus (QFT-Plus) is an in vitro diagnostic aid for detection of Mycobacterium tuberculosis infection Percent Antigen-specific T Cell DMSO-subtracted Cytokine Response Change from Baseline 13-color ICS assay using PBMCs T Cell: CD4+ Stimulation Antigen: Total Cytokine: Any","populationDescription":"Immunogenicity analysis set: LTBI-negative at baseline","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Percentage of change from baseline","timeFrame":"Day 292","groups":[{"id":"OG000","title":"2-Dose Placebo","description":"Placebo, QFT Neg and Pos, 2 doses day 0 and 56"},{"id":"OG001","title":"2-Dose 5/500 H56/IC31nmol","description":"5/500 H56ug/IC31nmol, QFT Neg and Pos, 2 Doses, days 0 and 56"},{"id":"OG002","title":"2-Dose 15/500 H56/IC31nmol","description":"15/500 H56ug/IC31nmol, QFT Negative, 2 Doses, days 0 and 56"},{"id":"OG003","title":"2-Dose 50/500 H56/IC31nmol","description":"50/500 H56ug/IC31nmol, QFT Negative, 2 Doses, days 0 and 56"},{"id":"OG004","title":"3-Dose Placebo","description":"Placebo QFT Neg and Pos, 3 Doses, days 0, 56, 112"},{"id":"OG005","title":"3-Dose 5/500 H56/IC31nmol","description":"5/500 H56ug/IC31nmol, QFT Neg and Pos, 3 Doses, days 0, 56, 112"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"14"},{"groupId":"OG003","value":"14"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"6"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.002","spread":"0.018"},{"groupId":"OG001","value":"0.088","spread":"0.104"},{"groupId":"OG002","value":"0.027","spread":"0.031"},{"groupId":"OG003","value":"0.031","spread":"0.047"},{"groupId":"OG004","value":"0.012","spread":"0.014"},{"groupId":"OG005","value":"0.045","spread":"0.056"}]}]}]},{"type":"SECONDARY","title":"Evaluate Immunogenicity of Multiple Dosage Levels and Dosing Regimens of H56:IC31 - CD4+ ICS (LTBI-positive)","description":"Percent Antigen-specific T Cell DMSO-subtracted Cytokine Response Change from Baseline.\n\n13-color ICS assay using PBMCs. T Cell: CD4+ Stimulation Antigen: Total Cytokine: Any","populationDescription":"Immunogenicity analysis set: LTBI-positive at baseline","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Percentage of change from baseline","timeFrame":"Day 292","groups":[{"id":"OG000","title":"2-Dose Placebo","description":"Placebo, QFT Neg and Pos, 2 doses day 0 and 56"},{"id":"OG001","title":"2-Dose 5/500 H56/IC31nmol","description":"5/500 H56ug/IC31nmol, QFT Neg and Pos, 2 Doses, days 0 and 56"},{"id":"OG002","title":"3-Dose Placebo","description":"Placebo QFT Neg and Pos, 3 Doses, days 0, 56, 112"},{"id":"OG003","title":"3-Dose 5/500 H56/IC31nmol","description":"5/500 H56ug/IC31nmol, QFT Neg and Pos, 3 Doses, days 0, 56, 112"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"8"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.005","spread":"0.020"},{"groupId":"OG001","value":"0.068","spread":"0.052"},{"groupId":"OG002","value":"0.027","spread":"0.022"},{"groupId":"OG003","value":"0.097","spread":"0.170"}]}]}]},{"type":"SECONDARY","title":"Evaluate Immunogenicity of Multiple Dosage Levels and Dosing Regimens of H56:IC31 - IFN-gamma ELISpot","description":"DMSO-subtracted Antigen-specific IFN-gamma ELISpot Response (SFU - Background/10\\^6 PBMC) Change from Baseline LTBI Status at Baseline: Total Stimulation Antigen: Total","populationDescription":"Immunogenicity analysis set","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"Number of spots per well","timeFrame":"Day 292","groups":[{"id":"OG000","title":"2-Dose Placebo","description":"Placebo, QFT Neg and Pos, 2 doses day 0 and 56"},{"id":"OG001","title":"2-Dose 5/500 H56/IC31nmol","description":"5/500 H56ug/IC31nmol, QFT Neg and Pos, 2 Doses, days 0 and 56"},{"id":"OG002","title":"2-Dose 15/500 H56/IC31nmol","description":"15/500 H56ug/IC31nmol, QFT Negative, 2 Doses, days 0 and 56"},{"id":"OG003","title":"2-Dose 50/500 H56/IC31nmol","description":"50/500 H56ug/IC31nmol, QFT Negative, 2 Doses, days 0 and 56"},{"id":"OG004","title":"3-Dose Placebo","description":"Placebo QFT Neg and Pos, 3 Doses, days 0, 56, 112"},{"id":"OG005","title":"3-Dose 5/500 H56/IC31nmol","description":"5/500 H56ug/IC31nmol, QFT Neg and Pos, 3 Doses, days 0, 56, 112"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"13"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"82.7","spread":"223.6"},{"groupId":"OG001","value":"209.0","spread":"221.8"},{"groupId":"OG002","value":"57.9","spread":"162.2"},{"groupId":"OG003","value":"110.0","spread":"92.0"},{"groupId":"OG004","value":"-53.1","spread":"79.8"},{"groupId":"OG005","value":"167.4","spread":"364.8"}]}]}]},{"type":"SECONDARY","title":"Evaluate Kinetics of QuantiFERON®-TB Gold Test (QFT) Responses in LTBI-negative Participants","description":"QFT results were summarized using subject count (percentage) for qualitative results.\n\nNumber of participants QFT-positive at any time point.","populationDescription":"Conversion of LTBI-negative at baseline to LTBI-positive due to H56:IC31 expression of ESAT-6 (antigen in QFT assay).","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Up to Study Day 292","groups":[{"id":"OG000","title":"Placebo QFT Neg","description":"2-doses and 3-doses (Groups 1 and 2)"},{"id":"OG001","title":"2-Doses 5/500 QFT Neg","description":"QFT Negative (Group 1)"},{"id":"OG002","title":"2-Doses 15/500","description":"QFT Negative (Group 1)"},{"id":"OG003","title":"2-Doses 50/500","description":"QFT Negative (Group 1)"},{"id":"OG004","title":"3-Doses 5/500 QFT Neg","description":"QFT Negative (Group 2)"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"15"},{"groupId":"OG003","value":"15"},{"groupId":"OG004","value":"12"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"7"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"0","timeFrame":"10 months","description":"Systematic Assessment - includes diary cards, scheduled visits and lab tests Non-systematic Assessment also collected through self reporting","eventGroups":[{"id":"EG000","title":"2-Dose Placebo","description":"Placebo QFT neg and pos","deathsNumAffected":0,"deathsNumAtRisk":9,"seriousNumAffected":0,"seriousNumAtRisk":9,"otherNumAffected":9,"otherNumAtRisk":9},{"id":"EG001","title":"2-Dose 5/500 H56ug/IC31nmol","description":"2-Dose 5/500 H56ug/IC31nmol, QFT neg and pos","deathsNumAffected":0,"deathsNumAtRisk":27,"seriousNumAffected":2,"seriousNumAtRisk":27,"otherNumAffected":25,"otherNumAtRisk":27},{"id":"EG002","title":"2-Dose 15/500 H56ug/IC31nmol","description":"2-Dose 15/500 H56ug/IC31nmol, QFT negative","deathsNumAffected":0,"deathsNumAtRisk":15,"seriousNumAffected":0,"seriousNumAtRisk":15,"otherNumAffected":15,"otherNumAtRisk":15},{"id":"EG003","title":"2-Dose 50/500 H56ug/IC31nmol","description":"2-Dose 50/500 H56ug/IC31nmol, QFT negative","deathsNumAffected":0,"deathsNumAtRisk":15,"seriousNumAffected":0,"seriousNumAtRisk":15,"otherNumAffected":15,"otherNumAtRisk":15},{"id":"EG004","title":"3-Dose Placebo","description":"3-Dose Placebo QFT neg and pos","deathsNumAffected":0,"deathsNumAtRisk":8,"seriousNumAffected":0,"seriousNumAtRisk":8,"otherNumAffected":6,"otherNumAtRisk":8},{"id":"EG005","title":"3-Dose 5/500 H56ug/IC31nmol","description":"3-Dose 5/500 H56ug/IC31nmol, QFT neg and pos","deathsNumAffected":0,"deathsNumAtRisk":24,"seriousNumAffected":0,"seriousNumAtRisk":24,"otherNumAffected":20,"otherNumAtRisk":24}],"seriousEvents":[{"term":"Pneumothorax traumatic","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":27},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":24}]},{"term":"Lumbar radiculopathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":27},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":24}]}],"otherEvents":[{"term":"Bradycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":8},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":24}]},{"term":"Abdominal pain","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":27},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":24}]},{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":24}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":27},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":15},{"groupId":"EG003","numEvents":4,"numAffected":3,"numAtRisk":15},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":24}]},{"term":"Toothache","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":8},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":24}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":24}]},{"term":"Chills","organSystem":"General disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG003","numEvents":4,"numAffected":4,"numAtRisk":15},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":8},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":24}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":3,"numAtRisk":9},{"groupId":"EG001","numEvents":5,"numAffected":5,"numAtRisk":27},{"groupId":"EG002","numEvents":6,"numAffected":3,"numAtRisk":15},{"groupId":"EG003","numEvents":7,"numAffected":5,"numAtRisk":15},{"groupId":"EG004","numEvents":3,"numAffected":2,"numAtRisk":8},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":24}]},{"term":"Injection site erythema","organSystem":"General disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":27},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":24}]},{"term":"Injection site pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":9},{"groupId":"EG001","numEvents":19,"numAffected":14,"numAtRisk":27},{"groupId":"EG002","numEvents":10,"numAffected":5,"numAtRisk":15},{"groupId":"EG003","numEvents":11,"numAffected":8,"numAtRisk":15},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":8},{"groupId":"EG005","numEvents":12,"numAffected":7,"numAtRisk":24}]},{"term":"Injection site swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":27},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":24}]},{"term":"Injection site warmth","organSystem":"General disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":27},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":24}]},{"term":"Malaise","organSystem":"General disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":27},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":24}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":27},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":8},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":24}]},{"term":"Seasonal allergy","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG002","numEvents":3,"numAffected":1,"numAtRisk":15},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":24}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":27},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":24}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":27},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG004","numEvents":2,"numAffected":1,"numAtRisk":8},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":24}]},{"term":"Pharyngitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":27},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":24}]},{"term":"Sinusitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":27},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG003","numEvents":3,"numAffected":2,"numAtRisk":15},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":24}]},{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":27},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":15},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":24}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":15},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":15},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":8},{"groupId":"EG005","numEvents":3,"numAffected":2,"numAtRisk":24}]},{"term":"Wound infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":27},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":24}]},{"term":"Contusion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":8},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":24}]},{"term":"Stab wound","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":24}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":27},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG005","numEvents":3,"numAffected":3,"numAtRisk":24}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":27},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":24}]},{"term":"Blood alkaline phosphatase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":15},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":24}]},{"term":"Blood bilirubin increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":8},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":24}]},{"term":"Blood pressure diastolic increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":24}]},{"term":"Blood pressure increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":27},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":8},{"groupId":"EG005","numEvents":3,"numAffected":2,"numAtRisk":24}]},{"term":"Blood pressure systolic decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":24}]},{"term":"Blood pressure systolic increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":27},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":15},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":15},{"groupId":"EG004","numEvents":3,"numAffected":2,"numAtRisk":8},{"groupId":"EG005","numEvents":4,"numAffected":3,"numAtRisk":24}]},{"term":"Blood urine present","organSystem":"Investigations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":8},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":24}]},{"term":"Haemoglobin decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":4,"numAffected":3,"numAtRisk":27},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":24}]},{"term":"Heart rate decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":24}]},{"term":"Lymphocyte count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":24}]},{"term":"Neutrophil count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":27},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":15},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":8},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":24}]},{"term":"Platelet count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":24}]},{"term":"Respiratory rate increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":3,"numAtRisk":9},{"groupId":"EG001","numEvents":25,"numAffected":13,"numAtRisk":27},{"groupId":"EG002","numEvents":21,"numAffected":13,"numAtRisk":15},{"groupId":"EG003","numEvents":19,"numAffected":11,"numAtRisk":15},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":24}]},{"term":"White blood cell count decreased","organSystem":"Investigations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":24}]},{"term":"White blood cell count increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":27},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":24}]},{"term":"White blood cells urine positive","organSystem":"Investigations","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":24}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":27},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG003","numEvents":3,"numAffected":2,"numAtRisk":15},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":24}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":27},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":24}]},{"term":"Musculoskeletal chest pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":24}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":27},{"groupId":"EG002","numEvents":6,"numAffected":5,"numAtRisk":15},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":15},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":8},{"groupId":"EG005","numEvents":3,"numAffected":2,"numAtRisk":24}]},{"term":"Neck pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":24}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":24}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":24}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG001","numEvents":7,"numAffected":4,"numAtRisk":27},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":15},{"groupId":"EG003","numEvents":4,"numAffected":4,"numAtRisk":15},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":8},{"groupId":"EG005","numEvents":4,"numAffected":4,"numAtRisk":24}]},{"term":"Glycosuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":24}]},{"term":"Haematuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":9},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":27},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG005","numEvents":0,"numAffected":0,"numAtRisk":24}]},{"term":"Proteinuria","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":27},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":15},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG005","numEvents":2,"numAffected":2,"numAtRisk":24}]},{"term":"Papule","organSystem":"Skin and subcutaneous tissue disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":24}]},{"term":"Systolic hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 16.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":9},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":27},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":15},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":8},{"groupId":"EG005","numEvents":1,"numAffected":1,"numAtRisk":24}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictiveAgreement":false},"pointOfContact":{"title":"Dr. Dereck Tait","organization":"Aeras","email":"dtait@aeras.org","phone":"27214424991"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot","hasProtocol":true,"hasSap":false,"hasIcf":false,"label":"Study Protocol","date":"2013-05-10","uploadDate":"2017-09-14T16:06","filename":"Prot_000.pdf","size":3633706}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09"},"conditionBrowseModule":{"meshes":[{"id":"D055985","term":"Latent Tuberculosis"}],"ancestors":[{"id":"D014376","term":"Tuberculosis"},{"id":"D009164","term":"Mycobacterium Infections"},{"id":"D000193","term":"Actinomycetales Infections"},{"id":"D016908","term":"Gram-Positive Bacterial Infections"},{"id":"D001424","term":"Bacterial Infections"},{"id":"D001423","term":"Bacterial Infections and Mycoses"},{"id":"D007239","term":"Infections"},{"id":"D000085343","term":"Latent Infection"}]}},"hasResults":true}